Moreover, recent research has indicated that these BC patients exhibit reduced sensitivity to anti-vascular endothelial growth factor-based therapy due to elevated systemic levels of interleukin-6 and fibroblast growth factor-266. Here, VEGFA is linked to breast cancer.